Effect of Intravitreal Bevacizumab Injection on Retinopathy of Prematurity

doi:10.3341/jkos.2015.56.10.1650

Journal List > J Korean Ophthalmol Soc > v.56(10) > 1010126

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Effect of Intravitreal Bevacizumab Injection on Retinopathy of Prematurity

Original Article

J Korean Ophthalmol Soc 2015;56(10):1650-1651.

Published online: 29 August 2015

DOI: https://doi.org/10.3341/jkos.2015.56.10.1650

Effect of Intravitreal Bevacizumab Injection on Retinopathy of Prematurity

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Kim SE, Rim TH, Lee CS. Effect of primary intravitreal bev-acizumab injection on stage 3 retinopathy of prematurity with plus signs. J Korean Ophthalmol Soc. 2015; 56:62–9.

2. Beer PM, Wong SJ, Hammad AM. . Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina. 2006; 26:871–6.

3. Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther. 2011; 27:623–7.

TOOLS

Similar articles